AstraZeneca drug discovery expert joins DDW track at SLAS2026
Mel Leveridge, Vice President, Assays, Profiling & Cell Sciences, AstraZeneca will be speaking at the DDW track Creating Cures: The role of lab automation in successful drug discovery at SLAS2026.

She will discuss The Role of Automation in Discovery at AstraZeneca.
You can register your interest here.
For the third year running DDW is organising this series of seminars at SLAS International Conference and Exhibition. Based on the SLAS2026 theme of Catalyze Discovery, these will be available to visitors of SLAS2026 (7-11 February 2026, Boston, USA).
This programme, Creating Cures: The role of lab automation in successful drug discovery at SLAS2026 – will highlight innovative research using technology in drug development and will be held in the Ignite Theater on 9 and 10 February
In this presentation, Leveridge – an established preclinical drug discovery leader with a track record of developing and inspiring diverse, high performing teams, to deliver innovative science and technology – will outline the critical role that automation plays in target identification and lead discovery at AstraZeneca. She will share case studies demonstrating the impact of automation in driving quality, scale, efficiency, and sustainability in areas including functional genomics, high throughput chemistry, hit identification and DMTA profiling.
The track is sponsored by Collaborative Drug Discovery (CDD), Brooks Automation and Thermo Fisher Scientific.
Let us know if you’re attending by registering your interest.
